NasdaqGM:ESPR

Stock Analysis Report

Executive Summary

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C).

Snowflake

Fundamentals

Flawless balance sheet with reasonable growth potential.

Share Price & News

How has Esperion Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.8%

NasdaqGM:ESPR

-0.4%

US Biotechs

0.3%

US Market


1 Year Return

21.9%

NasdaqGM:ESPR

-9.0%

US Biotechs

0.7%

US Market

ESPR outperformed the Biotechs industry which returned -8.8% over the past year.

ESPR outperformed the Market in United States of America which returned 0.8% over the past year.


Share holder returns

ESPRIndustryMarket
7 Day-1.8%-0.4%0.3%
30 Day-4.9%-1.0%0.4%
90 Day11.9%-8.9%0.6%
1 Year21.9%21.9%-8.2%-9.0%2.9%0.7%
3 Year183.6%183.6%15.4%11.4%47.0%37.2%
5 Year225.8%225.8%9.9%5.1%54.7%37.4%

Price Volatility Vs. Market

How volatile is Esperion Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Esperion Therapeutics undervalued based on future cash flows and its price relative to the stock market?

7.56x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Esperion Therapeutics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Esperion Therapeutics to establish if it is available at substantial discount.


Price Based on Earnings

Esperion Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.

Esperion Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Esperion Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

Esperion Therapeutics is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Esperion Therapeutics expected to perform in the next 1 to 3 years based on estimates from 11 analysts?

15.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Esperion Therapeutics's revenue is expected to grow significantly at over 20% yearly.

Esperion Therapeutics's earnings are expected to grow by 15.1% yearly, however this is not considered high growth (20% yearly).

Esperion Therapeutics's revenue growth is expected to exceed the United States of America market average.

Esperion Therapeutics's earnings growth is expected to exceed the United States of America market average.

Esperion Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Esperion Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Esperion Therapeutics performed over the past 5 years?

-35.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Esperion Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Esperion Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Esperion Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Esperion Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Esperion Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Esperion Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Esperion Therapeutics's financial position?


Financial Position Analysis

Esperion Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Esperion Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Esperion Therapeutics has no debt.

Esperion Therapeutics has no debt compared to 5 years ago when it was 0.1%.


Balance Sheet

Low level of unsold assets.

Esperion Therapeutics has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Esperion Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.

Esperion Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 32.8% each year.


Next Steps

Dividend

What is Esperion Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Esperion Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Esperion Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Esperion Therapeutics has not reported any payouts.

Unable to verify if Esperion Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Esperion Therapeutics has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Esperion Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Esperion Therapeutics's salary, the management and board of directors tenure and is there insider trading?

1.2yrs

Average management tenure


CEO

Tim Mayleben (57yo)

6.5yrs

Tenure

US$9,724,839

Compensation

Mr. Timothy M. Mayleben, also known as Tim, M.B.A., has been the Chief Executive Officer and President of Esperion Therapeutics, Inc. since December 2012. Mr. Mayleben serves as an Advisor to several biote ...


CEO Compensation Analysis

Tim's remuneration is higher than average for companies of similar size in United States of America.

Tim's compensation has increased whilst company is loss making.


Management Age and Tenure

1.2yrs

Average Tenure

52yo

Average Age

The average tenure for the Esperion Therapeutics management team is less than 2 years, this suggests a new team.


Board Age and Tenure

4.0yrs

Average Tenure

57yo

Average Age

The tenure for the Esperion Therapeutics board of directors is about average.


Insider Trading

More shares have been bought than sold by Esperion Therapeutics insiders in the past 3 months.


Recent Insider Transactions

BuyUS$200,00001 Apr 19
Timothy Mayleben
EntityIndividual
Role
President
Member of the Board of Directors
Shares5,000
Max PriceUS$40.00
BuyUS$217,40021 Mar 19
Timothy Mayleben
EntityIndividual
Role
President
Member of the Board of Directors
Shares5,000
Max PriceUS$43.48
SellUS$76,92521 Mar 19
Domain Associates, L.L.C.
EntityCompany
Shares1,700
Max PriceUS$45.25
SellUS$608,67121 Mar 19
Domain Associates, L.L.C.
EntityCompany
Shares13,629
Max PriceUS$44.66
BuyUS$2,494,35515 Mar 19
Bellevue Asset Management AG
EntityCompany
Shares50,000
Max PriceUS$49.89
BuyUS$243,65014 Mar 19
Timothy Mayleben
EntityIndividual
Role
President
Member of the Board of Directors
Shares5,000
Max PriceUS$48.73
BuyUS$3,303,25607 Jan 19
Bellevue Asset Management AG
EntityCompany
Shares80,000
Max PriceUS$41.29
BuyUS$1,995,72526 Dec 18
Bellevue Asset Management AG
EntityCompany
Shares50,000
Max PriceUS$39.91
BuyUS$2,864,07019 Dec 18
Bellevue Asset Management AG
EntityCompany
Shares60,000
Max PriceUS$47.73
SellUS$5,638,34306 Nov 18
Tavistock Life Sciences
EntityCompany
Shares100,000
Max PriceUS$60.28
BuyUS$2,306,97006 Aug 18
Bellevue Asset Management AG
EntityCompany
Shares50,000
Max PriceUS$46.14
BuyUS$2,088,30013 Jul 18
Bellevue Asset Management AG
EntityCompany
Shares50,000
Max PriceUS$41.77
BuyUS$1,973,80503 Jul 18
Bellevue Asset Management AG
EntityCompany
Shares50,000
Max PriceUS$39.48
BuyUS$2,314,22425 Jun 18
Bellevue Asset Management AG
EntityCompany
Shares60,000
Max PriceUS$38.57

Ownership Breakdown


Management Team

  • Rick Bartram (36yo)

    CFO & Corporate Secretary

    • Tenure: 1.4yrs
    • Compensation: $2.54m
  • Renee Marotta

    Head of Marketing

  • Marianne Andreach

    Senior Vice President

    • Tenure: 1.9yrs
  • Mark Glickman (52yo)

    Chief Commercial Officer

    • Tenure: 1.2yrs
    • Compensation: $9.12m
  • Bill Sasiela (52yo)

    Senior Vice President of Clinical Development

    • Tenure: 1.2yrs
  • Tim Mayleben (57yo)

    President

    • Tenure: 6.5yrs
    • Compensation: $9.72m
  • Ashley Hall

    Senior Vice President of Global Regulatory Affairs & Policy

    • Tenure: 1.2yrs
  • Narendra Lalwani (65yo)

    Executive Vice President of Research & Development

    • Compensation: $2.35m
  • Keith Lenden (45yo)

    Vice President of Corporate Development & Strategy

  • Alex Schwartz

    Senior Director of Investor Relations

    • Tenure: 1.1yrs

Board Members

  • Nicole Vitullo (61yo)

    Lead Independent Director

    • Tenure: 3.5yrs
    • Compensation: $311.66k
  • Tracy Woody (48yo)

    Director

    • Tenure: 0.1yrs
  • Scott Braunstein (55yo)

    Director

    • Tenure: 4.0yrs
    • Compensation: $305.63k
  • Jay Shepard (60yo)

    Director

    • Tenure: 1.1yrs
    • Compensation: $477.34k
  • Mark McGovern (65yo)

    Director

    • Tenure: 5.3yrs
    • Compensation: $287.35k
  • Tim Mayleben (57yo)

    President

    • Tenure: 9.3yrs
    • Compensation: $9.72m
  • Jeff Berkowitz (52yo)

    Director

    • Tenure: 1.5yrs
    • Compensation: $1.41m
  • Dan Janney (53yo)

    Director

    • Tenure: 6.6yrs
    • Compensation: $270.58k
  • Antonio Gotto (83yo)

    Director

    • Tenure: 5.4yrs
    • Compensation: $290.84k

Company Information

Esperion Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Esperion Therapeutics, Inc.
  • Ticker: ESPR
  • Exchange: NasdaqGM
  • Founded: 2008
  • Industry: biotechnology
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$1.324b
  • Shares outstanding: 26.92m
  • Website: Click here

Number of Employees


Location

  • Esperion Therapeutics, Inc.
  • 3891 Ranchero Drive
  • Suite 150
  • Ann Arbor
  • Michigan
  • 48108
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ESPRNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJan 1970
0ETDB (Deutsche Boerse AG)YesCommon StockDEEURJan 1970
0IIMLSE (London Stock Exchange)YesCommon StockGBUSDJan 1970

Biography

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). It ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/06/17 00:39
End of Day Share Price2019/06/14 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.